Our mission:
Immunotherapy that scales
Twilight exists to bring next-generation immunotherapy to the conditions—and patients—that current therapies leave behind. Chronic disease is rising fast, but today’s tools are built for rare cases, not real life.

We’re changing that. With a new class of injectable, precision immunotherapies, we’re training the body to protect itself—simply, affordably, and at scale.
Team
Founded by experts in neurology,
immunology, and biotech
Our team includes former Biogen and Merck leadership, peer-reviewed neurovirologists, and the researchers who first linked HERV-K to ALS. Backed by institutional grants and $60M in platform R&D.
Ajay Verma, MD, PhD
CEO, Co-Founder
  • Former exec. at Biogen, Novartis, Merck, >15 years Pharma
  • Multiple large & small biotech R&D leadership roles
  • 15 years Neurology practice, U.S. Army, Walter Reed Medical Center
  • MD, PhD, Johns Hopkins University
Rahul Bhansali, MBA
CBO, Co-Founder
  • Co-founded three companies, 3X C-suite, 2 exits
  • Industrial safety company achieved ~10X greater valuation 
  • 10 yrs. investment mgmt., project finance, hedge fund risk
  • MBA Babson; BS Finance & Int’l Bus. Penn State 
Marta Garcia-Montojo, PhD
Senior Director
  • Research fellow, NINDS, GeNeuro, Ramon Y Cajal Hospital, Clinico San Carlos Hospital
  • Expert in Neurovirology, Neurodegeneration, Immunology
  • Discovered value of HERV-K adaptive immunity in ALS
  • PhD, Universidad Complutense de Madrid
Amanda Zimmerman, PhD
Program Manager
  • Director Program Management, Axonis Therapeutics
  • Former Postdoctoral Fellow at Harvard Medical School
  • Expert in electrophysiology, pain, and neuropsych. disorders
  • Multiple academic, non-profit, VC, & small biotech roles
  • PhD, Georgia Institute of Technology
Scientific advisors
Avindra Nath, PhD
Scientific advisor
  • Clinical Director, NINDS
  • Senior Investigator, CNS Infections
  • Senior Investigator, CNS Infections
    Seminal work on HERV-K in ALS
  • Renowned expert HIV and COVID neurology 
Colin L Masters, MD
Scientific advisor
  • Professor, Florey Institute and The University of Melbourne
  • First to characterize amyloid protein in Alzheimer's
  • Globally renowned neuropathologist
Paul Maruff, PhD
Scientific advisor
  • Co-founder, Chief Innovation Officer, Cogstate
  • Former Professor, Florey Institute of Neuroscience and Mental Health
  • Expert biomedical researcher in Alzheimer's and other dementias
Eduardo Locatelli, MD, MPH
Clinical Advisor
  • Physician Executive Director, NSU
    Neuroscience Institute
  • Director, Cathy Husman ALS Center Neurology & Informatics SME
John Altin, PhD
Scientific advisor
  • Associate professor TGEN
  • Co-inventor of Pep-Seq technology
  • Expert in adaptive immune system, genomics and biotechnology
Wayne Koff, PhD
Scientific advisor
  • Founder and President, Next Frontier Advisors
  • Founder and former CEO, Human Immunome Project.
  • Former CSO, SVP at R&D at IAVI
Let's talk
We’re looking to partner with those who want to shape the future of immunotherapy.
Contact us